List of works - Hui Wang

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

scientific article published on 08 March 2007

Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

scientific article

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

scientific article

Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression

scientific article published on January 1, 2003

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

scientific article published on April 2002

Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

scientific article

Antisense approaches in drug discovery and development.

scientific article

Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity

scientific article

Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.

scientific article published in January 2003

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

scientific article

Antisense-based cancer therapeutics: are we there yet?

scientific article

BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction

scientific article published on 16 May 2017

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms

scientific article published in December 2003

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9

scientific article published on 01 June 2006

CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents

scientific article published on 01 January 2003

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway

scientific article published on 01 March 2007

Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography

scientific article published on 17 April 2006

Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine

scientific article published on 30 January 2004

Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics

scientific article published on 01 April 2007

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy

scientific article published on 3 May 2008

Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein

scientific article published on 21 November 2017

Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles

scientific article

Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action ⬇️

scientific article published on June 6, 2011

Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

scientific article published on June 2007

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms

scientific article

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

scientific article published on November 2006

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides

scientific article

Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.

scientific article

Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels

scientific article published on September 2005

Ginsenosides as anticancer agents: In vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action ⬇️

scientific article published on February 28, 2012

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice

scientific article

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.

scientific article published on February 2015

Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

scientific article published on July 2013

Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy

scientific article published on 01 August 2006

In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng

scientific article published on 22 August 2006

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA

scientific article published on 8 October 2015

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

scientific article published on 24 May 2008

JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21

scientific article

Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.

scientific article published on 25 April 2013

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology

scientific article

Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish

scientific article

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

scientific article

MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

scientific article published on 03 February 2004

NFAT as cancer target: mission possible?

scientific article

Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.

scientific article

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine

Novel MDM2 p53-independent functions identified through RNA silencing technologies

scientific article

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms

scientific article

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action

scientific article

Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules

scientific article

Oncogenes as novel targets for cancer therapy (part III): transcription factors

scientific article

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis

scientific article

Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors ⬇️

scientific article published on December 28, 2010

Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies

scientific article

Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

scientific article published in September 2002

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis

scientific article published on September 2006

Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents

scientific article

Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent

scientific article published on 3 May 2005

Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl

scientific article

Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy

scientific article published in March 2004

RYBP stabilizes p53 by modulating MDM2

scientific article

Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice

scientific article published on 8 March 2002

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models

scientific article published on February 2004

Recent advances in experimental molecular therapeutics for malignant gliomas

scientific article published in July 2004

Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications

scientific article

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway

scientific article

Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes

scientific article

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics

scientific article

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

scientific article published on 01 October 2014

Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53 ⬇️

scientific article published on July 11, 2012

Wnt/beta-catenin signaling pathway as a novel cancer drug target

scientific article

List of works by Hui Wang

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

Antisense approaches in drug discovery and development.

Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity

Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

Antisense-based cancer therapeutics: are we there yet?

BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9

CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway

Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography

Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine

Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy

Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein

Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles

Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action ⬇️

Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides

Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.

Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels

Ginsenosides as anticancer agents: In vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action ⬇️

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.

Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy

In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21

Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology

Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

NFAT as cancer target: mission possible?

Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine

Novel MDM2 p53-independent functions identified through RNA silencing technologies

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action

Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules

Oncogenes as novel targets for cancer therapy (part III): transcription factors

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis

Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors ⬇️

Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies

Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis

Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents

Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent

Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl

Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy

RYBP stabilizes p53 by modulating MDM2

Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models

Recent advances in experimental molecular therapeutics for malignant gliomas

Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway

Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53 ⬇️

Wnt/beta-catenin signaling pathway as a novel cancer drug target